Market Research Reports Pharmaceuticals for Women's Health: Global Markets | Page 2

- Country specific data and analysis for United States, Mexico, Germany, U.K., France,
China, India, Japan, Middle East and Africa
- A look at the regulatory environment which has been a driving force in the drug
development industry
- Information on competitor initiatives, and information with regard to demand for
specialty chemicals used to develop new products and for new applications
- A relevant patent analysis within the sector
- Comprehensive company profiles of major Players in the Market including AbbVie
Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson
Inc., Novo Nordisk and Pfizer Inc.
Summary
Women's health therapeutics have a strong presence in the global pharmaceutical
market, and that presence is expected to increase from approximately $x.x billion in
2017 to nearly $x.x billion by 2023, at a CAGR of x.x%. North America dominates the
global women’s health market, with a marketshare of x.x% in 2017. North America
will continue with its leading position, followed by Europe and Asia-Pacific, during
the forecast period.
The postmenopausal osteoporosis segment leads the global women's health
therapeutics and technologies market and will continue to significantly drive market
growth, followed by pregnancy disorders and management, menopause-related
conditions, endometriosis and polycystic ovary syndrome. Pharmaceutical
companies in the women's healthcare space are expanding their R&D base and
doubling efforts to expand beyond reproductive health into key women's health
areas, such as menopause-related conditions and osteoporosis. Existing therapies for
these health problems have issues pertaining to safety and efficacy; for instance,
hormone therapy comes with serious safety concerns. Therefore, there is growing
unmet need for better and safer products, particularly from growing elderly
populations. Osteoporosis, similar to hormone therapy, sees increasing demand due
to a growing older demographic, but safety concerns have curbed efforts to address
that demand. The bisphosphonate category, while regarded by physicians as safe
and effective, has suffered considerably over concerns of atypical fractures and
osteonecrosis of the jaw.
Women's health therapeutics have established a very strong presence in the global
pharmaceutical market over the last few decades. The market is expected to grow
moderately, mainly due to patent expirations of blockbuster drugs such as Evista, the
Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and several others.
However, the launch of new drugs in the market, and novel drugs under research
and development in the late-stage pipeline, has the strong potential to drive the
market during the forecast period.
The global women’s health therapeutics market is dominated by Eli Lilly; Amgen, Inc.;
Merck & Co, Inc.; AbbVie, Inc.; Bayer AG and Pfizer Inc. They held a significant share
of the global women’s health market in 2017. Tier 1 companies dominate the market